Vyome Reports Positive Phase 2 Data for VT-1953 Gel

Vyome Holdings ( (HIND) ) has issued an update.

Vyome Holdings reported Phase 2 investigator-sponsored trial results for VT-1953, a 2% topical gel for malignant fungating wounds, demonstrating statistically significant reductions in malodor by Day 14 versus both baseline and vehicle, with 80% of treated patients achieving a greater than two-point malodor improvement. The study, which also showed meaningful gains in patient-reported quality of life and pain relief with a favorable tolerability profile, underpins further clinical development of VT-1953 and reinforces Vyome’s strategic positioning in an underserved niche of supportive cancer care.

The most recent analyst rating on (HIND) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Vyome Holdings stock, see the HIND Stock Forecast page.

Spark’s Take on HIND Stock

According to Spark, TipRanks’ AI Analyst, HIND is a Neutral.

The score is held down primarily by deteriorating revenue, very large losses, and ongoing cash burn that increase financing/dilution risk. Technicals also indicate a sustained downtrend. Offsetting factors are modest: low current leverage and positive corporate updates around VT-1953’s perceived market potential, but these do not overcome the weak current financial profile.

To see Spark’s full report on HIND stock, click here.

More about Vyome Holdings

Vyome Holdings, Inc. operates in the biopharmaceutical sector, focusing on the development of topical drug candidates for oncology-related conditions. Its lead asset VT-1953 targets malignant fungating wounds, a rare complication affecting roughly 10% of advanced cancer patients and representing an estimated $2.2 billion annual U.S. market opportunity.

Average Trading Volume: 872,227

Technical Sentiment Signal: Strong Sell

Current Market Cap: $14.45M

Find detailed analytics on HIND stock on TipRanks’ Stock Analysis page.